Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study (Q28551624)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study	scientific article

Statements

scholarly article

0 references

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study (English)

0 references

1 reference

based on heuristic

inferred from title

Kiat Ruxrungtham

6

object named as

Kiat Ruxrungtham

0 references

Anchalee Avihingsanon

5

object named as

Anchalee Avihingsanon

0 references

Opass Putcharoen

7

object named as

Opass Putcharoen

0 references

author name string

Phairote Teeranaipong

1

0 references

Sunee Sirivichayakul

2

0 references

Suwanna Mekprasan

3

0 references

Pirapon June Ohata

4

0 references

language of work or name

0 references

publication date

2016

0 references

0 references

11

0 references

4

0 references

e0154221

0 references

copyright license

Creative Commons Attribution 4.0 International

27 April 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847912

19 March 2017

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847912

29 September 2017

Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847912

29 September 2017

The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847912

29 September 2017

The HIVdb system for HIV-1 genotypic resistance interpretation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847912

29 September 2017

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847912

29 September 2017

Five-year outcomes of the China National Free Antiretroviral Treatment Program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847912

29 September 2017

Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847912

29 September 2017

Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847912

3 June 2018

Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0154221

21 January 2018

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0154221

21 January 2018

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0154221

21 January 2018

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0154221

21 January 2018

Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0154221

21 January 2018

Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0154221

21 January 2018

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0154221

21 January 2018

Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0154221

21 January 2018

Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/27120449

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27120449

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails

1 reference

https://pubmed.ncbi.nlm.nih.gov/27120449

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rilpivirine: a step forward in tailored HIV treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/27120449

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0154221

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2016PLoSO..1154221T

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28551624&oldid=2057311645"